Janux Therapeutics Inc [JANX] stock is trading at $25.85, up 6.82%. An important factor to consider is whether the stock is rising or falling in short-term value. The JANX shares have gain 10.90% over the last week, with a monthly amount glided 6.33%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Janux Therapeutics Inc [NASDAQ: JANX] stock has seen the most recent analyst activity on September 17, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $47. Previously, Truist started tracking the stock with Buy rating on September 10, 2025, and set its price target to $100. On September 10, 2025, Stifel initiated with a Buy rating and assigned a price target of $45 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $72 on September 04, 2025. Piper Sandler initiated its recommendation with a Overweight and recommended $42 as its price target on August 19, 2025. Raymond James started tracking with an Outperform rating for this stock on July 11, 2025, and assigned it a price target of $65. In a note dated December 03, 2024, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $63 to $70.
Janux Therapeutics Inc [JANX] stock has fluctuated between $21.73 and $71.71 over the past year. Currently, Wall Street analysts expect the stock to reach $57.25 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $25.85 at the most recent close of the market. An investor can expect a potential return of 121.47% based on the average JANX price forecast.
Analyzing the JANX fundamentals
Janux Therapeutics Inc [NASDAQ:JANX] reported sales of 0.44M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.26% with Operating Profit Margin at 17.95%, Pretax Profit Margin comes in at 13.09%, and Net Profit Margin reading is 13.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.11 and Total Capital is -0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.52 points at the first support level, and at 23.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.61, and for the 2nd resistance point, it is at 27.38.
Ratios To Look Out For
For context, Janux Therapeutics Inc’s Current Ratio is 47.03. On the other hand, the Quick Ratio is 47.03, and the Cash Ratio is 2.45. Considering the valuation of this stock, the price to sales ratio is 3530.51, the price to book ratio is 1.55.
Transactions by insiders
Recent insider trading involved Meyer Andrew Hollman, Chief Business Officer, that happened on May 01 ’25 when 3333.0 shares were sold. Officer, ANDREW MEYER completed a deal on May 01 ’25 to buy 3333.0 shares. Meanwhile, Chief Business Officer Meyer Andrew Hollman sold 3334.0 shares on Apr 21 ’25.
